Vivek Subbiah: Super honored to deliver the lecture on “Precision Oncology Paradigm: Unlocking Phenotypic Plasticity, Resistance and Treatment” at the Brown University 2023 Legoretta Cancer Center Symposium.
Vivek Subbiah, the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, recently shared a post by Wakif S.El-Deiry on LinkedIn, adding:
“Super honored to deliver the lecture on “Precision Oncology Paradigm: Unlocking Phenotypic Plasticity, Resistance and Treatment” at the Brown University 2023 Legoretta Cancer Center Symposium. Two days packed with science talks from amazing speakers and Nobel prize winning researchers. Thanks to the amazing Wafik S. El-Deiry, MD, PhD, FACP and Sendurai Mani for the invite.”
Quoting Wafik S. El-Deiry’s post:
“Terrific engaging presentation by Vivek Subbiah, MD, Chief of Early-Phase Drug Development across Sarah Cannon Research Institute who inspired the audience with his presentation about successes in precision oncology. He has led quite a bit of this in the field including several drug approvals such as the most recent Ret inhibitors.”
Source: Vivek Subbiah/LinkedIn and Wafik S. El-Deiry/LinkedIn.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023